Biocartis Closes $41.3M Series B to Further Develop Molecular Dx Platform

The Swiss firm said that it will use the cash to accelerate development and validation of the first version of its forthcoming molecular diagnostics platform, which will incorporate nucleic acid sample prep technology recently acquired from Royal Philips Electronics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.